INMB - INmune Bio, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

INMB

INMUNE BIO, INC.

NASDAQ

$1.89

▲ UP 3.28% (0.06)

KEY STATISTICS

Market Cap$47.59 M

52w High$2.60

52w Low$1.09

Dividend Yield—

Frequency—

P/E-2.82

Volume91.63K

Shares Out.26.59M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

David J. Moss

COMPENSATION 2026

Salary$416,268

Stock Awards$1,428,911

Incentive Plan Pay$0

All Other Comp.$0

Total$1,845,179

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 4, 2019

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$22.00

Target Low$22.00

Target Median$22.00

Target Consensus$22.00

UPCOMING EARNINGS

DateOct 29, 2026

DayThursday

Rev. Est.$1.88M

OCT

THU

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

19.17%

HOLDERS

103

TOP 8 OF 103 · RANKED BY POSITION SIZE

Geode Capital Management, LLC

495.0K sh

$559.46K

Raymond James Financial Services Advisors, Inc.

Dauntless Investment Group, LLC

304.9K sh

$475.68K

PRICE

$1.89 ▲ UP 3.28% (+$0.06)

About INmune Bio, Inc.

https://www.inmunebio.com ↗

INmune Bio, Inc. is a clinical-stage immunotherapy company developing drugs to reprogram the innate immune system for treating cancers, inflammation, and Alzheimer's, with programs like INKmune, INB03, and XPro1595.

INDUSTRY

Biotechnology

A PRODUCT INMUNE BIO, INC. IS KNOWN FOR

CORDStrom™

INmune Bio's leading cell-based therapy, derived from umbilical cord mesenchymal stromal cells, is in late-stage development and has completed Phase 3 trials for treating the severe genetic skin disorder RDEB.

COMPETITORS

COMPETITOR

INmune Bio in 2025

SENTIMENT: → NEUTRAL

REGULATORY · JUNE 30, 2025

INmune Bio Announces Mixed Top-Line Results for Phase 2 Alzheimer's Trial of XPro™

On June 30, 2025, INmune Bio announced top-line results from its Phase 2 MINDFuL trial for its lead drug candidate, XPro™, in patients with early Alzheimer's disease. While the trial did not meet its primary cognitive endpoint in the overall modified intent-to-treat population, it did demonstrate a cognitive benefit in a predefined subgroup of patients with biomarkers of inflammation. This nuanced outcome generated significant discussion among investors and analysts regarding the future development path of the drug.

PRODUCT STRATEGY · JUNE/AUGUST 2025 · IN PROGRESS

INmune Bio Pivots Alzheimer's Strategy to Focus on Inflamed Patient Subgroup After Phase 2 Trial Misses Primary Endpoint

Following the release of top-line data from its MINDFuL Phase 2 trial in June 2025, INmune Bio made the strategic decision to focus the future development of its lead candidate, XPro™ (pegipanermin), on a predefined subgroup of early Alzheimer's patients with two or more biomarkers of inflammation. While the trial did not meet its primary cognitive endpoint in the broader study population, the company reported observing benefits in cognitive, behavioral, and biological endpoints within this 'enriched' population, prompting a targeted shift in its clinical and regulatory strategy.

Latest News

GLOBENEWSWIRE · OCT 6, 2026

INmune Bio to Attend the 2026 Maxim Growth Summit

BOCA RATON, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, is excited to announce its participation in the upcoming 2026 Maxim Growth Summit, taking place from October 12th to 14th at The Hard Rock Hotel NYC. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.

READ ARTICLE